Compare iShares MSCI India ETF (INDA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Koninklijke Philips NV — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while Koninklijke Philips NV trades at $24.24 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 4.1× iShares MSCI India ETF's market cap, and Koninklijke Philips NV pays a 4.17% dividend while iShares MSCI India ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and Koninklijke Philips NV for 84 Days on average.
| INDA | PHG | |
|---|---|---|
Market Cap | $5.73B | $23.52B |
Volume | 6,797,522 | 1,635,069 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $32.91 |
52-Week Low | $45.42 | $23.81 |
Typical Hold Time | 58 Days | 84 Days |
Enterprise Value | — | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $45.56, down 1.21% with bearish technical signals dominating. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and IT sector weakness. Technical indicators show oversold conditions with RSI readings below 20, while moving averages signal strong bearish momentum. Recent news highlights energy security concerns and pharmaceutical export challenges affecting the underlying Indian market exposure.
The outlook remains cautious given multiple sector-specific pressures in India. Investment opportunity exists for long-term investors betting on India's growth story at depressed levels, but risks include persistent energy shortages, agricultural output concerns, and global trade tensions that could further pressure the ETF's performance in the near term.
PHG trades at $24.30, up 0.87% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong cash flow generation. Recent news highlights product innovations including new CT systems and AI healthcare advancements, while institutional ownership shows mixed activity.
The outlook remains cautious with analyst consensus at Hold (63.64%) despite positive earnings momentum. Key risks include cybersecurity threats and competitive pressures in health technology. The stock presents a recovery opportunity but requires monitoring of execution risks and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
